Isoforms of Receptors of Fibroblast Growth Factors

Journal of Cellular Physiology

Volumn 229, Issue 12, 2014, Pages 1887-1895

  Gong, Siew Ging ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; FIBROBLAST GROWTH FACTOR RECEPTOR; ISOPROTEIN; LIGAND; TYROSINE KINASE RECEPTOR;

ALTERNATIVE RNA SPLICING; AMINO ACID SEQUENCE; AUTOPHOSPHORYLATION; BIRTH DEFECT; CELL PROLIFERATION; CELL SURVIVAL; CHONDROGENESIS; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; EXON; HUMAN; LIGAND BINDING; MESENCHYME; NONHUMAN; NONSENSE MEDIATED MRNA DECAY; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; TUMOR GROWTH;

ALTERNATIVE SPLICING; EXONS; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; LIGANDS; PROTEIN ISOFORMS; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84906673934     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24649     Document Type: Review

References (130)

1. Ahmad I, Iwata T, Leung HY. 2012. Mechanisms of FGFR-mediated carcinogenesis. Biochim Biophys Acta 1823:850-860.
2. Avivi A, Yayon A, Givol D. 1993. A novel form of FGF receptor-3 using alternative exon in the immunoglobulin domain III. FEBS Lett 330:249-252.
3. Baldridge D, Shchelochkov O, Kelley B, Lee B. 2010. Signaling pathways in human skeletal dysplasias. Annu Rev Genomics Hum Genet 11:189-217.
4. Barnard JC, Williams AJ, Rabier Bnd, Chassande O, Samarut J, Cheng S-Y, Bassett JHD, Williams GR. 2005. Thyroid hormones regulate fibroblast growth factor receptor signaling during chondrogenesis. Endocrinology 146:5568-5580.
5. Baum B, Settleman J, Quinlan MP. 2008. Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol 19:294-308.
6. Beadle GW, Tatum EL. 1941. Genetic control of biochemical reactions in neurospora. Proc Natl Acad Sci USA 27:499-506.
7. Beenken A, Mohammadi M. 2009. The FGF family: Biology, pathophysiology and therapy. Nat Rev Drug Discov 8:235-253.
8. Bernard O, Li M, Reid HH. 1991. Expression of two different forms of fibroblast growth factor receptor 1 in different mouse tissues and cell lines. Proc Natl Acad Sci USA 88:7625-7629.
9. Burgar HR, Burns HD, Elsden JL, Lalioti MD, Heath JK. 2002. Association of the signaling adaptor FRS2 with fibroblast growth factor receptor 1 (Fgfr1) is mediated by alternative splicing of the juxtamembrane domain. J Biol Chem 277:4018-4023.
10. Böttcher RT, Niehrs C. 2005. Fibroblast growth factor signaling during early vertebrate development. Endocr Rev 26:63-77.
11. Cha JY, Lambert QT, Reuther GW, Der CJ. 2008. Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis. Mol Cancer Res 6:435-445.
12. Cha JY, Maddileti S, Mitin N, Harden TK, Der CJ. 2009. Aberrant receptor internalization and enhanced FRS2-dependent signaling contribute to the transforming activity of the fibroblast growth factor receptor 2 IIIb C3 isoform. J Biol Chem 284:6227-6240.
13. Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED. 2006. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: Role of fibroblast growth factor receptor-2. Cancer Res 66:11271-11278.
14. Champion-Arnaud P, Ronsin C, Gilbert E, Gesnel M, Houssaint E, Breathnach R. 1991. Multiple mRNAs code for proteins related to the BEK fibroblast growth factor receptor. Oncogene 6:979-987.
15. Chasin LA. 2007. Searching for splicing motifs. Adv Exp Med Biol 623:85-106.
16. Chellaiah A, Yuan W, Chellaiah M, Ornitz DM. 1999. Mapping ligand binding domains in chimeric fibroblast growth factor receptor molecules. Multiple regions determine ligand binding specificity. J Biol Chem 274:34785-34794.
17. Cheon HG, LaRochelle WJ, Bottaro DP, Burgess WH, Aaronson SA. 1994. High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains. Proc Natl Acad Sci USA 91:989-993.
18. Christensen C, Berezin V, Bock E. 2011. Neural cell adhesion molecule differentially interacts with isoforms of the fibroblast growth factor receptor. Neuroreport 22:727-732.
19. de la Grange P, Gratadou L, Delord M, Dutertre M, Auboeuf D. 2010. Splicing factor and exon profiling across human tissues. Nucleic Acids Res 38:2825-2838.
20. Dorey K, Amaya E. 2010. FGF signalling: Diverse roles during early vertebrate embryogenesis. Development 137:3731-3742.
21. Drugan CS, Paterson IC, Prime SS. 1998. Fibroblast growth factor receptor expression reflects cellular differentiation in human oral squamous carcinoma cell lines. Carcinogenesis 19:1153-1156.
22. Duan DS, Werner S, Williams LT. 1992. A naturally occurring secreted form of fibroblast growth factor (FGF) receptor 1 binds basic FGF in preference over acidic FGF. J Biol Chem 267:16076-16080.
23. Dutertre M, Lacroix-Triki M, Driouch K, de la Grange P, Gratadou L, Beck S, Millevoi S, Tazi J, Lidereau R, Vagner S, Auboeuf D. 2010. Exon-based clustering of murine breast tumor transcriptomes reveals alternative exons whose expression is associated with metastasis. Cancer Res 70:896-905.
24. Eisemann A, Ahn J, Graziani G, Tronick S, Ron D. 1991. Alternative splicing generates at least five different isoforms of the human basic-FGF receptor. Oncogene 6:1195-1202.
25. Eswarakumar VP, Lax I, Schlessinger J. 2005. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16:139.
26. Faustino NA, Cooper TA. 2003. Pre-mRNA splicing and human disease. Genes Dev 17:419-437.
27. Gilbert W. 1978. Why genes in pieces? Nature 271:501.
28. Giri D, Ropiquet F, Ittmann M. 1999. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 5:1063-1071.
29. Grose R, Dickson C. 2005. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 16:179-186.
30. Groth C, Lardelli M. 2002. The structure and function of vertebrate fibroblast growth factor receptor 1. Int J Dev Biol 46:393-400.
31. Guillemot F, Zimmer C. 2011. From cradle to grave: The multiple roles of fibroblast growth factors in neural development. Neuron 71(4):574-588.
32. Hanneken A. 2001. Structural characterization of the circulating soluble FGF receptors reveals multiple isoforms generated by secretion and ectodomain shedding. FEBS Lett 489:176-181.
33. Harada H, Kettunen P, Jung HS, Mustonen T, Wang YA, Thesleff I. 1999. Localization of putative stem cells in dental epithelium and their association with Notch and FGF signaling. J Cell Biol 147:105-120.
34. Hattori Y, Odagiri H, Nakatani H, Miyagawa K, Naito K, Sakamoto H, Katoh O, Yoshida T, Sugimura T, Terada M. 1990. K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes. Proc Natl Acad Sci USA 87:5983-5987.
35. Holzmann K, Grunt T, Heinzle C, Sampl S, Steinhoff H, Reichmann N, Kleiter M, Hauck M, Marian B. 2012. Alternative splicing of fibroblast growth factor receptor IgIII loops in cancer. J Nucleic Acids 2012:950508.
36. Horlick RA, Stack SL, Cooke GM. 1992. Cloning, expression and tissue distribution of the gene encoding rat fibroblast growth factor receptor subtype 4. Gene 120:291-295.
37. Hou J, Kan M, Wang F, Xu JM, Nakahara M, McBride G, McKeehan K, McKeehan WL. 1992. Substitution of putative half-cystine residues in heparin-binding fibroblast growth factor receptors. Loss of binding activity in both two and three loop isoforms. J Biol Chem 267:17804-17808.
38. Hovhannisyan RH, Carstens RP. 2007. Heterogeneous ribonucleoprotein m is a splicing regulatory protein that can enhance or silence splicing of alternatively spliced exons. J Biol Chem 282:36265-36274.
39. Ibrahimi OA, Zhang F, Lang Hrstka SC, Mohammadi M, Linhardt RJ. 2004. Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assemblyâ€. Biochemistry 43:4724-4730.
40. Itoh K, Hattori Y, Sakamoto H. 1994. Preferential alternative splicing in cancer generates a K-sam messenger RNA with higher transforming activity. Cancer Res 54:3237-3241.
41. Jang JH, Chung CP. 2003. Loss of ligand-binding specificity of fibroblast growth factor receptor 2 by RNA splicing in human chondrosarcoma cells. Cancer Lett 191:215-222.
42. Jang JH, Shin KH, Park YJ, Lee RJ, McKeehan WL, Park JG. 2000. Novel transcripts of fibroblast growth factor receptor 3 reveal aberrant splicing and activation of cryptic splice sequences in colorectal cancer. Cancer Res 60:4049-4052.
43. Jiao J, Greendorfer JS, Zhang P, Zinn KR, Diglio CA, Thompson JA. 2003. Alternatively spliced FGFR-1 isoform signaling differentially modulates endothelial cell responses to peroxynitrite. Arch Biochem Biophys 410:187-200.
44. Jin W, Cote GJ. 2004. Enhancer-dependent splicing of FGFR1 alpha-exon is repressed by RNA interference-mediated down-regulation of SRp55. Cancer Res 64:8901-8905.
45. Jin W, Huang ES, Bi W, Cote GJ. 1998. Exon sequence is required for regulated RNA splicing of the human fibroblast growth factor receptor-1 alpha-exon. J Biol Chem 273:16170-16176.
46. Jin W, Huang ES, Bi W, Cote GJ. 1999. Redundant intronic repressors function to inhibit fibroblast growth factor receptor-1 alpha-exon recognition in glioblastoma cells. J Biol Chem 274:28035-28041.
47. Johnson D, Williams L. 1993. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 60:1-4.
48. Johnson DE, Lee PL, Lu J, Williams LT. 1990. Diverse forms of a receptor for acidic and basic fibroblast growth factors. Mol Cell Biol 10:4728-4736.
49. Johnson DE, Lu J, Chen H, Werner S, Williams LT. 1991. The human fibroblast growth factor receptor genes: A common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain. Mol Cell Biol 11:4627-4634.
50. Johnston CL, Cox HC, Gomm JJ, Coombes RC. 1995. Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments. A splice variant of FGFR-3 localizes to the nucleus. J Biol Chem 270:30643-30650.
51. Kalinina J, Dutta K, Ilghari D, Beenken A, Goetz R, Eliseenkova AV, Cowburn D, Mohammadi M. 2012. The alternatively spliced acid box region plays a key role in FGF receptor autoinhibition. Structure 20:77-88.
52. Kan M, Wang F, Xu J, Crabb JW, Hou J, McKeehan WL. 1993. An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science 259:1918-1921.
53. Kannan K, Givol D. 2000. FGF receptor mutations: Dimerization syndromes, cell growth suppression, and animal models. IUBMB Life 49:197-205.
54. Kettunen P, Karavanova I, Thesleff I. 1998. Responsiveness of developing dental tissues to fibroblast growth factors: expression of splicing alternatives of FGFR1, -2, -3, and of FGFR4; and stimulation of cell proliferation by FGF-2, -4, -8, and -9. Dev Genet 22:374-385.
55. Kettunen P, Laurikkala J, Itäranta P, Vainio S, Itoh N, Thesleff I. 2000. Associations of FGF-3 and FGF-10 with signaling networks regulating tooth morphogenesis. Dev Dyn 219:322-332.
56. Kobrin MS, Yamanaka Y, Friess H, Lopez ME, Korc M. 1993. Aberrant expression of type I fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res 53:4741-4744.
57. Kostrzewa M, Müller U. 1998. Genomic structure and complete sequence of the human FGFR4 gene. Mamm Genome 9:131-135.
58. Kwabi-Addo B, Ropiquet F, Giri D, Ittmann M. 2001. Alternative splicing of fibroblast growth factor receptors in human prostate cancer. Prostate 46:163-172.
59. Lin Y, Cheng YS, Qin C, Lin C, D'Souza R, Wang F. 2009. FGFR2 in the dental epithelium is essential for development and maintenance of the maxillary cervical loop, a stem cell niche in mouse incisors. Dev Dyn 238:324-330.
60. Lopez AJ. 1998. Alternative splicing of pre-mRNA: Developmental consequences and mechanisms of regulation. Annu Rev Genet 32:279-305.
61. Luqmani YA, Graham M, Coombes RC. 1992. Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast and comparison with other normal tissues. Br J Cancer 66:273-280.
62. Maquat LE. 2005. Nonsense-mediated mRNA decay in mammals J Cell Sci 118:1773-1776.
63. Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, McDermott LA, Coldren CD, Nemenoff RA, Merrick DT, Helfrich BA, Bunn PA, Heasley LE. 2009. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol 75:196-207.
64. Marie PJ, Miraoui H, Sévère N. 2012. FGF/FGFR signaling in bone formation: progress and perspectives. Growth Factors 30:117-123.
65. Matlin AJ, Clark F, Smith CW. 2005. Understanding alternative splicing: Towards a cellular code. Nat Rev Mol Cell Biol 6:386-398.
66. Matsuda Y, Hagio M, Seya T, Ishiwata T. 2012. Fibroblast growth factor receptor 2 IIIc as a therapeutic target for colorectal cancer cells. Mol Cancer Ther 11:2010-2020.
67. Mauger DM, Lin C, Garcia-Blanco MA. 2008. HnRNP H and hnRNP F complex with Fox2 to silence fibroblast growth factor receptor 2 exon IIIc. Mol Cell Biol 28:5403-5419.
68. McKeehan W, Wang F, Kan M. 1998. The heparan sulfate-fibroblast growth factor family: Diversity of structure and function. Prog Nucleic Acid Res Mol Biol 59:135-176.
69. McKeehan WL, Kan M. 1994. Heparan sulfate fibroblast growth factor receptor complex: Structure-function relationships. Mol Reprod Dev 39:62-81.
70. Mittendorf KF, Deatherage CL, Ohi MD, Sanders CR. 2012. Tailoring of membrane proteins by alternative splicing of pre-mRNA. Biochemistry 51:5541-5556.
71. Modrek B, Lee C. 2002. A genomic view of alternative splicing. Nat Genet 30:13-19.
72. Mohammadi M, Olsen SK, Ibrahimi OA. 2005. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 16:107-137.
73. Muenke M, Schell U. 1995. Fibroblast-growth-factor receptor mutations in human skeletal disorders. Trends Genet 11:308-313.
74. Nakatani H, Sakamoto H, Yoshida T, Yokota J, Tahara E, Sugimura T, Terada M. 1990. Isolation of an amplified DNA sequence in stomach cancer. Jpn J Cancer Res 81:707-710.
75. Nugent MA, Edelman ER. 1992. Kinetics of basic fibroblast growth factor binding to its receptor and heparan sulfate proteoglycan: A mechanism for cooperactivity. Biochemistry 31:8876-8883.
76. Olsen SK, Ibrahimi OA, Raucci A, Zhang F, Eliseenkova AV, Yayon A, Basilico C, Linhardt RJ, Schlessinger J, Mohammadi M. 2004. Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc Natl Acad Sci USA 101:935-940.
77. Oltean S, Bates DO. 2013. Hallmarks of alternative splicing in cancer. Oncogene. [Epub ahead of print]
78. Oltean S, Sorg BS, Albrecht T, Bonano VI, Brazas RM, Dewhirst MW, Garcia-Blanco MA. 2006. Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. Proc Natl Acad Sci USA 103:14116-14121.
79. Onwuazor ON, Wen XY, Wang DY, Zhuang L, Masih-Khan E, Claudio J, Barlogie B, Shaughnessy JD, Stewart AK. 2003. Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients. Blood 102:772-773.
80. Ornitz DM. 2000. FGFs, heparan sulfate and FGFRs: Complex interactions essential for development. Bioessays 22:108-112.
81. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M. 1996. Receptor specificity of the fibroblast growth factor family. J Biol Chem 271:15292-15297.
82. Orr-Urtreger A, Bedford MT, Burakova T, Arman E, Zimmer Y, Yayon A, Givol D, Lonai P. 1993. Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). Dev Biol 158:475-486.
83. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. 2008. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 40:1413-1415.
84. Pandya-Jones A, Black DL. 2009. Co-transcriptional splicing of constitutive and alternative exons. RNA 15:1896-1908.
85. Plotnikov AN, Hubbard SR, Schlessinger J, Mohammadi M. 2000. Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Cell 101:413-424.
86. Plotnikov AN, Schlessinger J, Hubbard SR, Mohammadi M. 1999. Structural basis for FGF receptor dimerization and activation. Cell 98:641-650.
87. Powers CJ, McLeskey SW, Wellstein A. 2000. Fibroblast growth factors, their receptors and signaling. Endocr-Relat Cancer 7:165-197.
88. Rapraeger AC, Guimond S, Krufka A, Olwin BB. 1994. Regulation by heparan sulfate in fibroblast growth factor signaling. Methods Enzymol 245:219-240.
89. Ricol D, Cappellen D, El Marjou A, Gil-Diez-de-Medina S, Girault JM, Yoshida T, Ferry G, Tucker G, Poupon MF, Chopin D, Thiery JP, Radvanyi F. 1999. Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene 18:7234-7243.
90. Roghani M, Moscatelli D. 2007. Prostate cells express two isoforms of fibroblast growth factor receptor 1 with different affinities for fibroblast growth factor-2. Prostate 67:115-124.
91. Root LL, Shipley GD. 2000. Normal human fibroblasts produce membrane-bound and soluble isoforms of FGFR-1. Mol Cell Biol Res Commun 3:87-97.
92. Ropiquet F, Giri D, Kwabi-Addo B, Mansukhani A, Ittmann M. 2000. Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer. Cancer Res 60:4245-4250.
93. Rose-John S, Heinrich PC. 1994. Soluble receptors for cytokines and growth factors: Generation and biological function. Biochem J 300:281-290.
94. Sahni M, Ambrosetti DC, Mansukhani A, Gertner R, Levy D, Basilico C. 1999. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev 13:1361-1366.
95. Sakaguchi K, Lorenzi MV, Bottaro DP, Miki T. 1999. The acidic domain and first immunoglobulin-like loop of fibroblast growth factor receptor 2 modulate downstream signaling through glycosaminoglycan modification. Mol Cell Biol 19:6754-6764.
96. Savagner P, Vallés AM, Jouanneau J, Yamada KM, Thiery JP. 1994. Alternative splicing in fibroblast growth factor receptor 2 is associated with induced epithelial-mesenchymal transition in rat bladder carcinoma cells. Mol Biol Cell 5(8):851-862.
97. Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, Yayon A, Linhardt RJ, Mohammadi M. 2000. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell 6:743-750.
98. Shi E, Kan M, Xu J, Wang F, Hou J, McKeehan W. 1993. Control of fibroblast growth factor receptor kinase signal transduction by heterodimerization of combinatorial splice variants. Mol Cell Biol 13:3907-3918.
99. Shimizu A, Tada K, Shukunami C, Hiraki Y, Kurokawa T, Magane N, Kurokawa-Seo M. 2001. A novel alternatively spliced fibroblast growth factor receptor 3 isoform lacking the acid box domain is expressed during chondrogenic differentiation of ATDC5 cells. J Biol Chem 276:11031-11040.
100. Shimizu A, Takashima Y, Kurokawa-Seo M. 2002. FGFR3 isoforms have distinct functions in the regulation of growth and cell morphology. Biochem Biophys Res Commun 290:113-120.
101. Takaishi S, Sawada M, Morita Y, Seno H, Fukuzawa H, Chiba T. 2000. Identification of a novel alternative splicing of human FGF receptor 4: soluble-form splice variant expressed in human gastrointestinal epithelial cells. Biochem Biophys Res Commun 267:658-662.
102. Terada M, Shimizu A, Sato N, Miyakaze S-i, Katayama H, Kurokawa-Seo M. 2001. Fibroblast growth factor receptor 3 lacking the Ig IIIb and transmembrane domains secreted from human squamous cell carcinoma DJM-1 binds to FGFs. Mol Cell Biol Res Commun 4:365-373.
103. Thesleff I. 2003. Developmental biology and building a tooth. Quintessence Int 34:613-620.
104. Thomson AA. 2001. Role of androgens and fibroblast growth factors in prostatic development. Reproduction 121:187-195.
105. Tomlinson DC, Knowles MA. 2010. Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer. Am J Pathol 177:2379-2386.
106. 2 splice site (/GA) in alternative splicing by fibroblast growth factor receptors 1, 2 and 3. Human Mol Genet 7:685-691.
107. Vainikka S, Partanen J, Bellosta P, Coulier F, Birnbaum D, Basilico C, Jaye M, Alitalo K. 1992. Fibroblast growth factor receptor-4 shows novel features in genomic structure, ligand binding and signal transduction. EMBO J 11:4273-4280.
108. Valve E, Martikainen P, Seppänen J, Oksjoki S, Hinkka S, Anttila L, Grenman S, Klemi P, Härkönen P. 2000. Expression of fibroblast growth factor (FGF)-8 isoforms and FGF receptors in human ovarian tumors. Int J Cancer 88:718-725.
109. Vickers SM, Huang ZQ, MacMillan-Crow L, Greendorfer JS, Thompson JA. 2002. Ligand activation of alternatively spliced fibroblast growth factor receptor-1 modulates pancreatic adenocarcinoma cell malignancy. J Gastrointest Surg 6:546-553.
110. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB. 2008. Alternative isoform regulation in human tissue transcriptomes. Nature 456:470-476.
111. Wang F, Kan M, Xu J, Yan G, McKeehan WL. 1995. Ligand-specific structural domains in the fibroblast growth factor receptor. J Biol Chem 270:10222-10230.
112. Wang F, Lu W, McKeehan K, Mohamedali K, Gabriel JL, Kan M, McKeehan WL. 1999. Common and specific determinants for fibroblast growth factors in the ectodomain of the receptor kinase complex. Biochemistry 38:160-171.
113. Wang XP, Suomalainen M, Felszeghy S, Zelarayan LC, Alonso MT, Plikus MV, Maas RL, Chuong CM, Schimmang T, Thesleff I. 2007. An integrated gene regulatory network controls stem cell proliferation in teeth. PLoS Biol 5:e159.
114. Warzecha CC, Carstens RP. 2012. Complex changes in alternative pre-mRNA splicing play a central role in the epithelial-to-mesenchymal transition (EMT). Semin Cancer Biol 22:417-427.
115. Warzecha CC, Jiang P, Amirikian K, Dittmar KA, Lu H, Shen S, Guo W, Xing Y, Carstens RP. 2010. An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition. EMBO J 29:3286-3300.
116. Warzecha CC, Sato TK, Nabet B, Hogenesch JB, Carstens RP. 2009. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell 33:591-601.
117. Warzecha CC, Shen S, Xing Y, Carstens RP. 2009. The epithelial splicing factors ESRP1 and ESRP2 positively and negatively regulate diverse types of alternative splicing events. RNA Biol 6:546-562.
118. Werner S, Duan DS, de Vries C, Peters KG, Johnson DE, Williams LT. 1992. Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities. Mol Cell Biol 12:82-88.
119. Wesche J, Haglund K, Haugsten E. 2011. Fibroblast growth factors and their receptors in cancer. Biochem J 437:199-213.
120. Wheldon LM, Khodabukus N, Patey SJ, Smith TG, Heath JK, Hajihosseini MK. 2011. Identification and characterization of an inhibitory fibroblast growth factor receptor 2 (FGFR2) molecule, up-regulated in an Apert Syndrome mouse model. Biochemical J 436:71-81.
121. Wilkie AO. 2005. Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev 16:187-203.
122. Xu J, Nakahara M, Crabb JW, Shi E, Matuo Y, Fraser M, Kan M, Hou J, McKeehan WL. 1992. Expression and immunochemical analysis of rat and human fibroblast growth factor receptor (flg) isoforms. J Biol Chem 267:17792-17803.
123. Xu Y, Piston DW, Johnson CH. 1999. A bioluminescence resonance energy transfer (BRET) system: Application to interacting circadian clock proteins. Proc Natl Acad Sci USA 96:151-156.
124. Yamaguchi F, Saya H, Bruner JM, Morrison RS. 1994. Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci 91:484-488.
125. Yan G, Fukabori Y, McBride G, Nikolaropolous S, McKeehan WL. 1993. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 13:4513-4522.
126. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. 1991. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64:841-848.
127. Yoshino M, Ishiwata T, Watanabe M, Komine O, Shibuya T, Tokunaga A, Naito Z. 2005. Keratinocyte growth factor receptor expression in normal colorectal epithelial cells and differentiated type of colorectal cancer. Oncol Rep 13:247-252.
128. Yu K, Ornitz DM. 2001. Uncoupling fibroblast growth factor receptor 2 ligand binding specificity leads to Apert syndrome-like phenotypes. Proc Natl Acad Sci USA 98:3641-3643.
129. Zhang P, Greendorfer JS, Jiao J, Kelpke SC, Thompson JA. 2006. Alternatively spliced FGFR-1 isoforms differentially modulate endothelial cell activation of c-YES. Arch Biochem Biophys 450:50-62.
130. Zhang Y, Gorry MC, Post JC, Ehrlich GD. 1999. Genomic organization of the human fibroblast growth factor receptor 2 (FGFR2) gene and comparative analysis of the human FGFR gene family. Gene 230:69-79.